Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

  • Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.
  • The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized.
  • Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2, and the lower incidents of hospitalization associated with it, have made clinical investigations challenging to execute in this evolving environment. 
  • Related: Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19.
  • Molecular Partners is collaborating with Novartis AG (NYSE:NVS), which is engaging with the FDA to align on a potential Phase 3 study design that could provide the additional data the agency is seeking for the EUA or full regulatory approval.
  • Price Action: MOLN shares are down 35.2% at $9.00, and NVS stock is up 0.16% at $89.10 during the premarket session on Wednesday's last check. 
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.